Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Transcranial Direct Current Stimulation (tDCS) can Reduce Fatigue and Improve Sleep Quality in Multiple Sclerosis
Neuro-rehabilitation
P7 - Poster Session 7 (5:30 PM-6:30 PM)
15-007

To test whether anodal transcranial direct current stimulation (tDCS) over primary motor cortex (M1) reduces fatigue and improves sleep quality in multiple sclerosis (MS).

Transcranial direct current stimulation (tDCS) is an emerging non-invasive brain stimulation technique that can reduce MS-related fatigue and may positively affect neural pathways involved in arousal and sleep.

MS participants were randomly assigned to complete 10 sessions of either active (2.5 mA) or sham tDCS targeting M1 (anode over C3/cathode over FP2) paired with unloaded cycling for 20 minutes. Fatigue was measured with the 21-item Modified form of the Fatigue Impact Scale (MFIS) at baseline, treatment end, and at a 3-week follow-up. An actigraphy device was worn on nondominant wrist throughout the study in order to measure sleep efficiency (SE), total sleep time (TST) and wake after sleep onset (WASO). Daily sleep quality scores were aggregated to represent baseline, end of tDCS treatment, and 3-week follow-up. Two-way repeated measures-ANOVA (Time, Treatment) was performed to investigate differences between active and sham conditions.

Twelve MS participants were enrolled: n=6 active (age 48.8±13.2 years, EDSS 3.5 to 6.5) and n=6 sham (53.5±8.9 years, EDSS 3.5 to 6.5). Post-hoc analysis revealed a significant reduction of fatigue score (MFIS) after active treatment (Baseline vs. End Treatment, 42.7 vs. 31.4, p<0.001). The active group reported an improvement in sleep quality, including  an increase in SE (Baseline vs. End Treatment, 89.5 vs 93.77 %, p<0.05) and TST (Baseline vs. End Treatment, 347.2 vs. 415.5 min, p<0.05), and a reduction trend for WASO (Baseline vs. End Treatment, 39.5 vs. 22.5 min), with no significant differences detected in the sham group.

Repeated application of anodal tDCS over M1 can reduce fatigue in MS. This effect may be consequent to the efficacy of tDCS in modulating sleep patterns.

Authors/Disclosures
Giuseppina Pilloni, PhD (NYU Grossman School of Medicine)
PRESENTER
Dr. Pilloni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ceragem.
Claire Sunha Choi, MD Ms. Choi has nothing to disclose.
Michael Shaw No disclosure on file
Lauren B. Krupp, MD, FÂé¶¹´«Ã½Ó³»­ (NYU Langone Medical Center) Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EBIX. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman LaRoche. Dr. krupp has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MMMK. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Patrick, Dolan, and Kaufman. Dr. krupp has received intellectual property interests from a discovery or technology relating to health care.
Leigh E. Charvet, PhD (NYU Langone) Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson & Johnson. Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springer Healthcare. Dr. Charvet has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for YBrain. Dr. Charvet has stock in Johnson&Johnson.